Is there a need for adjusting the results of the recent meta-analysis on the novel oral anticoagulants in atrial fibrillation to the baseline CHADS2 score?

Abstract

[1] Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension. The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the ManagementofArterialHypertensionof the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462–536. [2] Rabi DM, Daskalopoulou SS, Padwal RS, et al. Canadian Hypertension Education Program. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011;27:415–33. [3] Ogihara T, KikuchiK,MatsuokaH, et al. The JapaneseSocietyofHypertensionguidelines for the management of hypertension (JSH 2009). Hypertens Res 2009;32:3–107. [4] Chiang CE,Wang TD, Li YH, et al. 2010 guidelines of the TaiwanSociety of Cardiology for the management of hypertension. J Formos Med Assoc 2010;109:740–73. [5] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52. [6] Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308–47. [7] Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011;57:2037–114. [8] Okin PM, Kjeldsen SE, Julius S, et al. Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study. Heart Rhythm 2012;9:531–7. [9] Myerburg R, Castellanos A. Cardiac arrest and sudden cardiac death. In: Libby P, Bonow R, Mann D, Zipes D, Braunwald E, editors. Braunwald's heart disease. Philadelphia, USA: Saunders Elsevier; 2008. p. 933–74. [10] Olgin J, Zipes D. Specific arrhythmias: diagnosis and treatment. In: Libby P, Bonow R, Mann D, Zipes D, Braunwald E, editors. Braunwald's heart disease. Philadelphia, USA: Saunders Elsevier; 2008. p. 863–922. [11] Singh BN. Beta-adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview. J Cardiovasc Pharmacol Ther 2005;10(Suppl 1):S3–S14. [12] Coats AJ, Shewan LG. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1–2.